Dicloxacillin pharmacokinetics

Putnam W, Desai DG, Hung Y, Woo JM, Benet LZ. The effect of induction conditions and MDR1 genotypes on dicloxacillin pharmacokinetics [abstr]. Clin Pharm Ther 2003 73 57. 

Putnam WS, Woo JM, Huang Y, Benet LZ. Effect of the MDRl C3435T vaxiant and P-glyco-protein induction on dicloxacillin pharmacokinetics. JC/zw Pharmacol 45,411-21. 

J. T. Doluisio, J. C. LaPiana, and L. W. Dittert, Pharmacokinetics of ampicillin trihydrate, sodium ampicillin, and sodium dicloxacillin following intramuscular injection, J. Pharm. Sci, 60, 715-719 (1971). 

Levitt, D.G., PKQuest capillary permeability limitation and plasma protein binding — application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics, BMC Clin. Pharmacol., 2, 7,2002. 

For oral therapy, cloxaciUin and dicloxacillin are comparable alternatives. Both undergo hepatic metabolism, and neither drug requires dose adjustment in patients with hepatic insufficiency. Additional pharmacokinetic data are in Table 45.1. Indications for cloxacillin or dicloxacillin include clinically mild staphylococcal infections like impetigo. 

Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M (1992) Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 15 154—161 Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCOIBI polymorphism on the pharmacokinetics of atorvastatm and losuvastatin. Clin Pharmacol... 

---

See also in sourсe #XX -- [ ]

---